Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMD NASDAQ:LIVN NASDAQ:LQDA NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMDInMode$13.770.0%$13.81$12.72▼$16.74$872.09M1.971.00 million shs265,654 shsLIVNLivaNova$69.99-0.1%$64.02$41.01▼$72.78$3.82B0.82806,946 shs99,989 shsLQDALiquidia$51.52-3.0%$37.66$11.85▼$53.93$4.55B0.411.67 million shs1.18 million shsTMDXTransMedics Group$63.96-0.5%$111.35$63.24▼$156.00$2.22B2.071.03 million shs325,187 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMDInMode-1.36%-4.44%+1.77%-5.81%-4.77%LIVNLivaNova-2.46%+14.90%+11.64%+5.04%+59.08%LQDALiquidia+25.32%+39.30%+37.82%+31.06%+246.80%TMDXTransMedics Group-5.44%-35.71%-43.60%-53.84%-42.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMDInMode$13.770.0%$13.81$12.72▼$16.74$872.09M1.971.00 million shs265,654 shsLIVNLivaNova$69.99-0.1%$64.02$41.01▼$72.78$3.82B0.82806,946 shs99,989 shsLQDALiquidia$51.52-3.0%$37.66$11.85▼$53.93$4.55B0.411.67 million shs1.18 million shsTMDXTransMedics Group$63.96-0.5%$111.35$63.24▼$156.00$2.22B2.071.03 million shs325,187 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMDInMode-1.36%-4.44%+1.77%-5.81%-4.77%LIVNLivaNova-2.46%+14.90%+11.64%+5.04%+59.08%LQDALiquidia+25.32%+39.30%+37.82%+31.06%+246.80%TMDXTransMedics Group-5.44%-35.71%-43.60%-53.84%-42.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMDInMode 2.00Hold$16.0016.19% UpsideLIVNLivaNova 2.70Moderate Buy$77.2210.18% UpsideLQDALiquidia 2.92Moderate Buy$46.78-11.96% DownsideTMDXTransMedics Group 2.50Moderate Buy$135.00109.95% UpsideCurrent Analyst Ratings BreakdownLatest INMD, TMDX, LQDA, and LIVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026LQDALiquidia Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/11/2026LQDALiquidia Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.005/11/2026LQDALiquidia Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $70.005/11/2026LQDALiquidia BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $59.005/7/2026LIVNLivaNova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C)5/7/2026LIVNLivaNova BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$73.00 ➝ $76.005/7/2026INMDInMode BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$21.00 ➝ $19.005/7/2026INMDInMode Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$17.00 ➝ $14.005/7/2026LIVNLivaNova MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$85.00 ➝ $90.005/7/2026LIVNLivaNova Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$78.00 ➝ $76.005/6/2026TMDXTransMedics Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$152.00 ➝ $124.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMDInMode$370.49M2.35$1.47 per share9.36$10.78 per share1.28LIVNLivaNova$1.39B2.77$4.72 per share14.86$21.98 per share3.19LQDALiquidia$158.32M29.83N/AN/A$0.51 per share104.18TMDXTransMedics Group$605.49M3.67$3.72 per share17.27$13.79 per share4.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMDInMode$93.83M$1.3610.13N/AN/A23.27%13.47%11.95%7/23/2026 (Estimated)LIVNLivaNova-$242.47M$1.9535.9417.18N/A7.48%16.48%7.59%N/ALQDALiquidia-$68.92M-$0.83N/A18.26N/A-43.53%-209.33%-25.32%N/ATMDXTransMedics Group$190.29M$4.4014.6117.28N/A27.04%22.38%8.46%7/30/2026 (Estimated)Latest INMD, TMDX, LQDA, and LIVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026LQDALiquidia$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million5/6/2026Q1 2026INMDInMode$0.2978$0.25-$0.0478$0.18$79.84 million$82.02 million5/6/2026Q1 2026LIVNLivaNova$0.85$0.98+$0.13$0.40$346.05 million$362.26 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 million3/18/2026Q4 2025LQDALiquidia$0.01$0.15+$0.14N/AN/AN/A3/5/2026Q4 2025LQDALiquidia$0.08$0.15+$0.07$0.15$87.49 million$92.02 million2/25/2026Q4 2025LIVNLivaNova$0.80$0.86+$0.06$0.56$354.31 million$360.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINMDInModeN/AN/AN/AN/AN/ALIVNLivaNovaN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMDInModeN/A8.807.88LIVNLivaNova0.241.331.11LQDALiquidia2.972.011.84TMDXTransMedics Group1.706.746.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMDInMode68.04%LIVNLivaNova97.64%LQDALiquidia64.54%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipINMDInMode6.92%LIVNLivaNova0.35%LQDALiquidia25.60%TMDXTransMedics Group6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMDInMode48063.36 million58.98 millionOptionableLIVNLivaNova3,30054.93 million54.74 millionOptionableLQDALiquidia5088.89 million66.14 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableINMD, TMDX, LQDA, and LIVN HeadlinesRecent News About These CompaniesTransMedics Group (NASDAQ:TMDX) Reaches New 52-Week Low - Here's Why4 hours ago | marketbeat.comAssessing TransMedics Group (TMDX) Valuation After A Sharp One Year Share Price DeclineMay 11 at 10:38 AM | finance.yahoo.comWall Street Zen Downgrades TransMedics Group (NASDAQ:TMDX) to SellMay 9 at 1:34 AM | marketbeat.comTransMedics Group, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 8, 2026 | seekingalpha.comTransMedics Group Inc (TMDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...May 8, 2026 | finance.yahoo.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of "Moderate Buy" by AnalystsMay 8, 2026 | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by BrokeragesMay 8, 2026 | marketbeat.comTransMedics Group (TMDX) Gets a Buy from NeedhamMay 7, 2026 | theglobeandmail.comTransMedics Group (NASDAQ:TMDX) Price Target Cut to $85.00 by Analysts at Stifel NicolausMay 7, 2026 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Lowered to "Market Perform" Rating by OppenheimerMay 7, 2026 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Price Target Lowered to $142.00 at Needham & Company LLCMay 7, 2026 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Given New $120.00 Price Target at Piper SandlerMay 7, 2026 | americanbankingnews.comTransMedics Group (NASDAQ:TMDX) Price Target Cut to $120.00 by Analysts at TD CowenMay 7, 2026 | americanbankingnews.comTransMedics Group Stock Watch: Healthcare Growth in FocusMay 6, 2026 | kalkinemedia.comKTransMedics tumbles after earnings missMay 6, 2026 | seekingalpha.comTransMedics: Cheaper, But Still Priced For PerfectionMay 6, 2026 | seekingalpha.comTransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity GroupMay 6, 2026 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD CowenMay 6, 2026 | marketbeat.comStifel Nicolaus Cuts TransMedics Group (NASDAQ:TMDX) Price Target to $85.00May 6, 2026 | marketbeat.comTMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins FallMay 6, 2026 | zacks.comPiper Sandler Issues Pessimistic Forecast for TransMedics Group (NASDAQ:TMDX) Stock PriceMay 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINMD, TMDX, LQDA, and LIVN Company DescriptionsInMode NASDAQ:INMD$13.76 -0.01 (-0.04%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.LivaNova NASDAQ:LIVN$69.99 -0.10 (-0.14%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.Liquidia NASDAQ:LQDA$51.52 -1.61 (-3.04%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.TransMedics Group NASDAQ:TMDX$63.96 -0.35 (-0.54%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
